<DOC>
	<DOCNO>NCT00973557</DOCNO>
	<brief_summary>The purpose research determine whether drug , Bevacizumab ( monoclonal anti VEGF-A antibody ) , approve treat patient metastatic colon cancer induces hyperprolactinemia ( increase prolactin secretion ) humans intact pituitary function . Past study show Bevacizumab shrink tumor size also increase prolactin level . The mechanism hyperprolactinemia might inhibition pituitary portal vein transport , suggest Bevacizumab induces prolactin secretion normal lactotrophs pituitary gland . Patients treat Bevacizumab least one month recruit participate . The subject treat Bevacizumab Dr. Stephen Wolin ( sub-investigator ) screen study eligibility . Dr. Wolin approach eligible patient information background study see interest consent . If consent , 2 blood draw research part standard care 10 ml blood collect prolactin , growth hormone , IGF-I , TSH , thyroxine , ACTH , cortisol measure . One 5ml blood draw occur administration Bevacizumab second 5 ml blood draw occur administration Bevacizumab . The investigator review laboratory result . The blood test hormones pituitary gland test pituitary function see abnormality secretion gland . Pituitary function abnormality hyperprolactinemia diagnose look hormone level blood compare normal reference range . This study involve 10 subject conduct entirely Cedars-Sinai Medical Center .</brief_summary>
	<brief_title>The Effect Monoclonal Vascular Endothelial Growth Factor ( VEGF ) Antibody ( Bevacizumab ) Pituitary Function</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients colorectal cancer , lung cancer , breast cancer , glioblastoma patient treat Bevacizumab least 1 month Adults ( 18 year age old ) Patients take medication know affect serum prolactin level Patients pregnant Patients pituitary disease Minors ( Under age 18 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>bevacizumab</keyword>
</DOC>